Search
Diagnostic solutions for precision oncology
Precision medicine is transforming cancer care, offering more targeted and effective treatment options. With the advent of advanced technologies like next-generation sequencing (NGS), clinicians and lab professionals can now rapidly identify key genomic markers that guide therapy decisions.
These tools enable personalized treatments, tailored to each patient’s unique molecular profile. As the number of molecularly targeted therapies continues to grow, timely access to this information is more critical than ever.
Rapid solid tumor diagnostics with Ion Torrent and Oncomine NGS
Thermo Fisher Scientific provides a range of diagnostic solutions for solid tumor biomarker testing, helping clinicians identify patients eligible for targeted therapies. These solutions are powered by our trusted Ion Torrent and Oncomine NGS technologies, delivering rapid and reliable clinical insights.
As in vitro diagnostic (IVD) regulations and oncology market needs vary across countries and regions, we offer a portfolio of solutions to meet specific clinical and regulatory requirements worldwide.
Oncomine Dx Express Test (CE-IVD)** |
CE-marked IVD solution for genomic profiling of multiple solid tumors
|
Ready to speak to a Thermo Fisher Scientific representative?
We will be happy to answer your questions about bringing NGS to your laboratory.
**Oncomine Dx Express Test (CE-IVD) Abbreviated Intended Use: The Oncomine Dx Express Test is a qualitative in vitro diagnostic test that uses targeted next-generation sequencing (NGS) technology and the Ion Torrent Genexus Dx System to detect deletions, insertions, substitutions, and copy number gain present in 42 genes and fusions in 18 genes from DNA and RNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples. The Oncomine Dx Express Test also detects deletions, insertions and substitutions in 42 genes and fusions in 7 genes from cfTNA extracted from plasma samples. The Oncomine Dx Express Test is intended to provide clinically relevant tumor mutation profiling information to be used by qualified health care professionals in accordance with professional guidelines as an aid in therapy management of cancer patients with solid malignant neoplasms using FFPE samples and as an aid in therapy management of cancer patients with non-small cell lung cancer using plasma samples. It is not conclusive or prescriptive for labeled use of any specific therapeutic product.
** For In Vitro Diagnostic Use. Not available in all countries, including the United States.
CN: 63956